Although obesity is a common co-morbid condition in COPD, relatively little is known how it may affect functional exercise capacity. Accordingly, we compared physiologic responses during a 6 min walk test in 10 obese and 10 non-obese COPD patients matched by gender, age, and spirometric severity category. Patients first exercised on a treadmill to determine maximal exercise responses, then following a rest period they completed a 6 min walk test. Breath by-breath analyses of expired air via a facemask was obtained using a portable, battery operated device. Oxygen consumption (VO 2 ), carbon dioxide production (VCO 2 ), tidal volume (VT), respiratory rate (RR), minute ventilation (VE), and inspiratory capacity (IC) were compared.
. Obese patients had shorter 6 min walk distances than non-obese patients (247 AE 73 vs 348 AE 51 m, respectively, p Z 0.003), but walk-work, defined as 6 min walk distance Â weight (in kg), was not different. There were no significant between-group differences in any exercise variable measured during the 6 min walk test. In both groups, VO 2 and VE increased linearly over the first 2e3 min, then plateaued at approximately 80% of maximum. Although 6 min walk distance is shorter in obese COPD patients, their physiologic responses are similar to those of non-obese patients. ª 2011 Elsevier Ltd. All rights reserved.
Introduction
Both chronic obstructive pulmonary disease (COPD) and obesity are prevalent in the developed world. For example, the pooled prevalence of physiologically-defined COPD in adults was approximately 10% in a systematic review and meta-analysis of data from 28 countries. 1 Likewise, the World Health Organization predicts that, by 2015, around 700 million adults will be obese; this represents at least 10% of the projected global population. 2 Therefore it is to be expected that these two conditions should frequently co-exist. Indeed, the prevalence of obesity in a primary care population of patients with COPD has been estimated to be about 18%, 3 and abdominal obesity has approximately twice the prevalence in COPD patients participating in pulmonary rehabilitation. 4 COPD is characterized by progressive expiratory flow limitation, gas exchange abnormalities, and static and dynamic hyperinflation. 5 Additionally, systemic effects of the disease, such as peripheral muscle deconditioning, are common. 5 These primary respiratory and systemic abnormalities contribute to the dyspnea, exercise intolerance, functional status limitation, and impairment in health status in COPD. In obesity, increased adipose tissue around the thorax and abdomen and in the visceral cavity places an additional load on the chest wall, resulting in reduced resting lung volumes such as the functional residual capacity and expiratory reserve volume. 10, 11 Although obesity has no direct effect on airway caliber, the low FRC increases the likelihood of expiratory flow limitation and airway closure, causing hypoxemia from ventilation-perfusion mismatching. 10 Respiratory muscle weakness, as evidenced by reduced maximal inspiratory pressures, may also be present in obesity. 12 Dyspnea, the cardinal symptom of COPD, is also common in obesity, 13 probably related to the above-described respiratory physiologic abnormalities, increased work requirements with exercise, and (possibly) the presence of co-morbid conditions.
Obese COPD patients have shorter 6 min walk distances than non-obese patients, although their walk-work (the product of walk distance in m and body weight in kg) is similar.
14 This suggests that their poorer lower extremity exercise performance reflects the increased work burden of obesity. The influence of obesity as a co-morbid condition on dyspnea and exercise tolerance in COPD was studied by Ora and associates. Physiologic responses during cycle ergometry in 18 obese and 18 non-obese patients with COPD were compared. 15 They demonstrated that the lower lung volumes associated with obesity ameliorated the static and dynamic hyperinflation in COPD, resulting in less dyspnea (at iso-ventilation) and increased oxygen uptake. The use of a cycle ergometer in this setting, however, potentially reduces the effects of the increased weight burden on exercise performance. Accordingly, we designed this study to evaluate exercise physiology and performance during walking, a more natural form of exercise in COPD patients.
Methods

Subjects
The study was approved by our Institutional Review Board and informed consent was obtained in all participants. We studied 20 COPD patients: 10 obese class II-III patients as categorized by the World Health Organization (BMI greater than 35 kg/m 2 16 ) and 10 matched non-obese (BMI less than 30 kg/m 2 but greater than 21 kg/m 2 ) patients. Underweight patients were excluded to reduce the potentially confounding effects of nutritional depletion on exercise outcomes. Other inclusion criteria included: 1) A clinical diagnosis of COPD; 2) An FEV1/FVC < 0.70; 3) An FEV1 > 30% of predicted, 4) Clinical stability in the respiratory disease for at least one month; 5) No perceived clinical contraindications to exercise testing; 6) The clinical expectation that oxygen saturation by pulse oximetry will remain above 85% during exercise testing. Patients requiring supplemental oxygen and those with co-morbid conditions that would put them at risk during exercise testing were excluded.
Subject matching
Obese and non-obese subjects were matched by age (AE5 years), gender, and Global Initiative for Obstructive Lung Disease (GOLD) 17 spirometric severity categories. GOLD spirometric classification is as follows: mild, FEV1/FVC < 0.70 and FEV1 ! 80% predicted; moderate, FEV1/FVC < 0.70 and FEV1 < 80% and predicted and !50%; and severe, FEV1/ FVC < 0.70 and FEV1 < 50% predicted and !30%. GOLD very severe (FEV1 30% predicted) were excluded since they were likely to oxygen-desaturate with exercise.
Study design
This was a non-blinded, parallel observational study comparing physiologic responses during the 6 min walk test in matched obese and non-obese COPD patients. Demographic data analyzed included gender, age, smoking history, co-morbid conditions, medications, height, weight, and body-mass index (kg/m 2 ). Pulmonary functions studies were obtained at baseline, with measurements of forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), diffusing capacity (DLCO), and inspiratory capacity (IC). Pulmonary function testing followed American Thoracic Society performance criteria. Maximal voluntary ventilation was estimated by multiplying the FEV1 by 35. 18 Following pulmonary function testing, an incremental cardiopulmonary exercise test was performed on a treadmill to a symptom-limited maximum. Treadmill testing was performed to determine physiologic variables at maximal exercise. Following a warm-up walk at 1 mph and zero percent grade, treadmill speed was increased at 1 -min intervals to the patient's stated normal brisk walking pace. After 1 min at this speed, the treadmill incline was increased by 1% every minute until the symptom-limited maximum. Twelve-lead ECG monitoring and oxygen saturation by pulse oximetry were assessed continuously. Breath-by-breath analysis of expired air was obtained using the Oxycon Mobile (Viasys Healthcare GmbH, Hoechberg, Germany). This is a portable, battery operated system mounted on the body via a vest. Breath-by-breath data was collected through a facemask and sent to the host computer system via wireless transmission. Oxygen consumption (VO 2 ), carbon dioxide production (VCO 2 ), tidal volume (VT), respiratory rate (RR), and minute ventilation (VE) were measured. Predicted maximal heart rate was determined by subtracting the patient's age from 220. Dyspnea and leg fatigue were rated at 1 -min intervals using 10-point category scales. IC measurements were obtained at 2 min intervals using the portable metabolic device.
After at least a 30 min rest, 6 min walk testing was performed. For this test, patients were instructed to walk as far as possible up and down an unrestricted corridor for 6 min. Rest periods were allowed and standardized encouragement was offered after each minute. Borg ratings of dyspnea and leg fatigue were obtained at 1-min intervals. A practice test was not given. A 12-lead ECG and oxygen saturation were recorded continuously during testing. Breath-by-breath analyses of expired air were also recorded, expressed as 1-min averages. IC measurements were recorded at 2-min intervals. Metabolic assessments and IC determinations were obtained using the same Oxycon Mobile device used for incremental treadmill testing. The physiologic variables during the 6 min walk test were expressed as absolute values and as percents of their respective values determined during the prior incremental treadmill testing.
Data analysis
Data are expressed as means AE standard deviations. Group comparisons of demographic, pulmonary function, and exercise variables were made using paired t-tests (SAS). 19 When comparing oxygen consumption during the 6 min walk testing, walk distance was added as covariate in a general linear model. A p < 0.05 was considered significant.
Results
Demographic and pulmonary function variables in the two groups are given in Table 1 . Each group consisted of 5 males and 5 females. The mean weight of obese patients was 103 AE 11 kg and 75 AE 14 kg in non-obese patients. The mean BMI of the obese group, 37 AE 02 kg/m 2 , is consistent with a class II obese categorization by the WHO. 16 The mean age and FEV1 percent-predicted were not significantly different, reflecting our matching of the two groups by age and GOLD spirometric category. In obese patients, the FVC was significantly lower (2.37 AE 0.59 vs 2.94 AE 0.88 L, respectively, p Z 0.02), and the DLCO tended to be lower (57 AE 8 vs 51 AE 14 respectively, p Z 0.07) than non-obese patients. Other pulmonary function variables were also not significantly different between groups. Six obese and 3 non-obese patients were taking oral beta-blockers for hypertension. Groups were similar with respect to inhaled steroid and long acting beta agonist use (5 and 6 per group, respectively), and long-acting anticholinergic (3 and 4, respectively) .
Physiologic variables at maximal exercise during treadmill testing for the two groups are given in Table 2 . In obese patients, the primary symptom limiting exercise was dyspnea in 8 and fatigue in 2; in non-obese patients all had dyspnea as the primary symptom. Obese patients tended to have a lower maximal heart rate, expressed as a percent of predicted, than non-obese patients: 70 AE 07 vs 81 AE 13%, respectively, p Z 0.05. Peak VO 2 , expressed as mL/kg/min was lower in obese than non-obese patients: 11.3 AE 2.2 vs 14.2 AE 3.4 mL/kg/min, respectively, p Z 0.03. Peak VO 2 , expressed as L/min, on the other hand was similar in both groups. Both obese and non-obese patients demonstrated significant hyperinflation at maximal treadmill exercise as determined by decreases in IC: À0.83 AE 0.60 L (p Z 0.002) and À0.63 AE 0.83 L (p Z 0.04), respectively. The betweengroup changes in IC were not significant (p Z 0.54). There were no group differences in respiratory rate at peak exercise.
The mean 6 min walk distance in obese patients was significantly less than non-obese patients: 247 AE 73 vs 348 AE 51 m, respectively, p Z 0.003. However, walk work, defined by the equation, 6 min walk distance Â weight (in kg), was not significantly different: 25721 AE 9211 vs 26381 AE 7202, respectively, p Z 0.85.
Physiologic variables measured at the end of the 6 min walk test are given in Table 3 . There were no significant between-group differences in any exercise variable. VO 2 , expressed as L/min, tended to be higher in obese than nonobese subjects (0.91 AE 0.30 vs 0.73 AE 0.27, respectively, p Z 0.29). Even after adjusting for the z100 m between- group difference in 6 min walk distance, the VO 2 difference remained non-significant (p Z 0.13). None of the patients in either group reached a respiratory exchange ratio >1.0, suggesting that none reached an anaerobic threshold. VO 2 measurements at the end of each minute during the 6 min walk test are depicted in Fig. 1a and b. In both groups, VO 2 increased in a linear fashion during the first 2 min then appeared to plateau. The VO 2 , expressed as L/min (Fig. 1a) tended to be higher in obese patients, but differences were non-significant at all time points. VO 2 , expressed as a percent of the maximal value achieved on treadmill testing (Fig. 1b) , was remarkably similar in both groups, plateauing at approximately 80%. VE followed the same general pattern as VO 2 , although the plateau appeared at approximately the 3rd minute. There were no significant between-group differences in VE at any time point. IC, which was measured at baseline and minutes 2, 4, and 6, decreased in both groups by the 2-min observation, then appeared to plateau in both groups. Between-group differences were not significant in this variable.
Discussion
Obesity is frequently present in COPD patients and may affect their symptoms, functional status and prognosis. Despite this, relatively few studies have assessed the effect of this co-morbid condition on outcomes. Accordingly, we compared physiologic variables measured during the 6 min walk test in obese and non-obese COPD patients matched by age, gender, and spirometric severity category.
The two groups (5 males, 5 females in each) were reasonably matched with respect to age, FEV1, inspiratory capacity and diffusing capacity. The lower FVC percentpredicted in the obese patients probably represents a restrictive abnormality associated with obesity. On preliminary treadmill exercise testing, heart rates at peak exercise were lower in obese than non-obese patients: 70 AE 7 versus 81 AE 13 percent of predicted maximal, respectively. Some of this difference may have been due to a higher frequency of beta blocker use in the obese patients. Peak VO 2 , expressed in L/min, was similar in both Abbreviations: HR Z heart rate; RR Z respiratory rate; VO 2 Z oxygen consumption; VE Z minute ventilation; VE/MVV Z ratio of minute ventilation to maximal voluntary ventilation; RER Z respiratory exchange ratio (VO/VCO 2 ). groups, although obese patients had a lower peak VO 2 when expressed as mL/kg/min. The obese group walked approximately 100 m less on their 6 min walk test than their non-obese counterparts. This difference is similar to that observed in a retrospective analysis of 114 COPD patients completing pulmonary rehabilitation at one center.
14 In that study, COPD patients with a BMI > 30 kg/m 2 , despite having a higher FEV1, had a 66 m shorter walk distance. Interestingly, amount of work performed during the walk test, as estimated by walk-work (weight Â walk distance), in both studies was nearly identical in obese and non-obese patients. Therefore, it appears that the shorter distance covered by obese patients was matched by increased load.
Despite the differences in distance, physiologic responses during the 6 min walk test were remarkably similar in both groups. VO 2 and VE increased in a linear fashion over the first 2e3 min of walking, then appeared to plateau at approximately 75% of their maximal value that was determined from incremental treadmill testing. The IC dropped early and similarly during the walk test in both groups then plateaued. This suggests that increases in lung hyperinflation occur early during walk test exercise.
Dyspnea and leg fatigue responses were also similar in both groups. Therefore, quite remarkably, the physiologic responses during the 6 min walk test appear to be similar in obese and non-obese COPD patients.
Our results from the 6 min walk test are very similar to those from a study of 20 COPD patients (BMI Z 28 kg/m 2 , FEV1 Z 45%) by Troosters and colleagues, 20 who showed a plateau in VO 2 beginning at the 3rd minute and VE beginning at the 4th minute of walking. As the authors indicate, a steady-state VO 2 appears to be a distinct feature of the 6 min walk test in COPD. The VE at the end of the 6 min walk in the Troosters study averaged 91% of the MVV, indicating substantial ventilatory limitation to this exercise. In contrast the VE/MVV at the end of the 6 min walk in our study was less than 50% in both groups. The reason(s) for this discrepancy are unclear, but it may relate to methodological issues (we estimated MVV from the FEV1) or differences in COPD in the two populations.
Peak VO 2 , expressed as L/min, at the end of the 6 min walk test tended to be higher in the obese COPD group, but differences were not significant. This probably reflects the small number of subjects in our study. Indeed, our study results contrast with those of Ora and colleagues. 20 and Laviolette and colleagues 21 who demonstrated that obese COPD patients had higher peak symptom-limited oxygen uptake than non-obese patients. The authors from the former study suggested this increased performance was related to less resting lung hyperinflation.
In summary, obese COPD patients had shorter 6 min walk distances but the total amount of work performed during this test was similar to matched non-obese patients. This suggests that, at least for functional exercise capacity, the increased metabolic load associated with obesity offsets the potential beneficial influence of lower resting lung volumes. Physiologic responses during the walk test indicate the attainment of a steady-state by the second to third minute of walking. This was evidenced by VO 2 and VE values at approximately 75% of the maximal values determined during treadmill testing. Physiologic responses of obese patients were very similar to non-obese patients during the walk test. shows VO 2 expressed as L/minute, while Fig. 1b shows VO 2 expressed as a percentage of the maximal value determined during treadmill exercise testing. In both groups, VO 2 increased in an apparent linear fashion up to 2 min, and then plateaued. Although VO 2 in L/min tended to be higher in obese patients, differences were not significant. Both groups plateaued at approximately 80% of their maximum determined from treadmill testing.
